Synbio International Inc

With our strategic licensing &manufacturing agreement with MDPHDWellness in place, we’re advancing aggressively toward commercialization. Focus now: brand awareness, acquiring customers & building a scalable direct-to-consumer sale platform. Groundwork done. Time to execute $SYIN

FacialDx is more than just an idea. It’s the beginning of a journey toward meaningful innovation, and we are just getting started. We look forward to sharing more as this important initiative progresses. The future starts with the first step. $SYIN

As CEO, I believe innovation has the power to change lives. We are excited about the potential of the FacialDx initiative and the opportunity to advance technology at the intersection of artificial intelligence and mental health. $SYIN

Manufacturing & revenue generation are now firmly within sight. After years of development by medical & scientific professionals, $SYIN is excited to enter its next phase of laying the groundwork for meaningful revenue generation. Thank you to our shareholders for your support.

We hear shareholders’ concerns about dilution, and protecting long-term shareholder value remains a priority. Our focus is earning revenue, strengthening $SYIN’s capital structure, and building a stronger foundation for the future. Stay tuned.

As CEO, building a strong business is only part of my responsibility. Creating meaningful value for shareholders is equally important & remains a top priority. I’m confident that the progress made will speak for itself & that the market will see the value we are creating $SYIN

$SYIN CEO Update: Synbio is advancing a dual-track healthcare strategy: building the Healing Force nutraceutical business & clinical validation of FacialDx’s NIMS mental health screening technology. Review the update here tinyurl.com/3wf7actb #MentalHealth #Nutraceuticals

The CEO of FacialDx, Doug Benoit and I in Australia this week. We met with the team at Resonance Health to begin planning the mental health clinical trial. Exciting progress as we move toward validation. #SYIN #Facialdx #mentalhealth #healthtech

Great to see the interest in what is an important development in mental health. biotech-insider.com/ai-power…

Working on the Statement of Work, trial timeline, and projected costs of the trial. The time is tight for an objective, rapid tool to help identify mental health conditions — we’re seeing meaningful progress now. #SYIN #MentalHealth #AI

Synbio has signed an agreement with a leading clinical research organization to conduct a clinical trial evaluating a proactive, non-invasive, AI-powered facial analysis test for PTSD and depression.  Mental health deserves better tools - and a new approach is taking shape. #SYIN

I was delighted to recently host a Director from our Australian CRO for the upcoming feasibility trial. Conducting the trial in Australia offers major Forex cost & tax advantages + a CRO with deep expertise and a proven FDA track record. #SYIN #MedTech #AIHealth #ClinicalTrials

A major step forward. Great to have Dr Vatakis on board. globenewswire.com/news-relea… $SYIN

Things are moving nicely. New early-revenue opportunities have been identified with FacialDx, complementing the facial-analysis medtech. And stay tuned for more soon on a great development at FacialDx and another SYIN key executive appointment. 🚀 $SYIN #MedTech #AI #MentalHealth

Last week in NYC I caught up with my good friend Doug Benoit, CEO of FacialDx. We discussed the enormous potential of facial analysis & finalized a press release for tomorrow re a closer tie between our companies, enabling $SYIN to share in the ownership of the facial-analysis IP

Really excited to have announced today the first of our board appointments. Ms Desiree Cain as Synbio’s CFO. Great addition to the executive team and I’m very much looking forward to working with her. This marks the beginning of Synbio’s next phase of growth. $SYIN

Great to welcome Doug Benoit CEO of FacialDx to NYC. We explored major opportunities in facial analysis, met with an investment bank about future funding and strengthened collaboration agreements. Press releases coming soon as we advance validation & commercialisation initiatives

We know that shareholders are eager for updates. Rest assured we are making good progress whilst going through the necessary legal & corporate checks and balances. Your patience is very much appreciated. We look forward to the rollout & sharing all the details with you very soon